Question: Consider the following statements:
(1) Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.
(2) Itolizumab is repurposed form of ALZUMAb launched in India in 2013 for treating chronic plaque psoriasis.
Of the above correct statement/s is/are:
(a) Only 1
(b) Only 2
(c) Both 1&2
(d) None of the above
Answer: (c)
Related facts:
- Drugs Controller General of India’s (DCGI) has given market approval to the Itolizumab Injection.
- The medicine will be used for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19.
- Itolizumab is the first novel biologic therapy to be approved anywhere in the world for treating patients with moderate to severe COVID-19 complications.
- It will be manufactured and formulated as an intravenous injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru.
- Itolizumab is repurposed form of ALZUMAb launched in India in 2013 for treating chronic plaque psoriasis.
- Clinical trial of the Itolizumab was conducted at multiple hospitals in Mumbai and New Delhi.
By-Amar Mani Upadhyay
Links:
https://www.biocon.com/biocon_press_release_20200711.asp